Literature DB >> 23543304

A physiologically based pharmacokinetic model for strontium exposure in rat.

Henry Pertinez1, Marylore Chenel, Leon Aarons.   

Abstract

PURPOSE: To develop a physiologically based pharmacokinetic (PBPK) model to describe the disposition of Strontium--a bone seeking agent approved in 2004 (as its Ranelate salt) for treatment of osteoporosis in post-menopausal women.
METHODS: The model was developed using plasma and bone exposure data obtained from ovariectomised (OVX) female rats--a preclinical model for post-menopausal osteoporosis. The final PBPK model incorporated elements from literature models for bone seeking agents allowing for description of the heterogeneity of bone tissue and also for a physiological description of bone remodelling processes. The model was implemented in MATLAB in open and closed loop configurations, and fittings of the model to exposure data to estimate certain model parameters were carried out using nonlinear regression, treating data with a naïve-pooled approach.
RESULTS: The PBPK model successfully described plasma and bone exposure of Strontium in OVX rats with parameter estimates and model behaviour in keeping with known aspects of the distribution and incorporation of Strontium into bone.
CONCLUSIONS: The model describes Strontium exposure in a physiologically rationalized manner and has the potential for future uses in modelling the PK-PD of Strontium, and/or other bone seeking agents, and for scaling to model human Strontium bone exposure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543304     DOI: 10.1007/s11095-013-0991-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  45 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Modeling the interactions between osteoblast and osteoclast activities in bone remodeling.

Authors:  Vincent Lemaire; Frank L Tobin; Larry D Greller; Carolyn R Cho; Larry J Suva
Journal:  J Theor Biol       Date:  2004-08-07       Impact factor: 2.691

3.  Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed.

Authors:  L Aarons
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

4.  Quantification of strontium in plasma and urine with flameless atomic absorption spectrometry.

Authors:  O R Leeuwenkamp; W J van der Vijgh; B C Hüsken; P Lips; J C Netelenbos
Journal:  Clin Chem       Date:  1989-09       Impact factor: 8.327

Review 5.  Strontium ranelate: a novel mode of action leading to renewed bone quality.

Authors:  Patrick Ammann
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

Review 6.  Strontium ranelate: a novel mode of action optimizing bone formation and resorption.

Authors:  P J Marie
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

7.  Physiologically based models for bone-seeking elements. II. Kinetics of lead disposition in rats.

Authors:  E J O'Flaherty
Journal:  Toxicol Appl Pharmacol       Date:  1991-11       Impact factor: 4.219

Review 8.  Bone as an effect compartment : models for uptake and release of drugs.

Authors:  David Stepensky; Lilach Kleinberg; Amnon Hoffman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

10.  Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.

Authors:  Björn Jobke; Andrew J Burghardt; Burkhard Muche; Michael Hahn; Jutta Semler; Michael Amling; Sharmila Majumdar; Björn Busse
Journal:  PLoS One       Date:  2011-08-16       Impact factor: 3.240

View more
  3 in total

Review 1.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

2.  A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.

Authors:  Jing-Tao Lu; Ying Cai; Feng Chen; Wei-Wei Jia; Zhe-Yi Hu; Yuan-Sheng Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

3.  A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.

Authors:  Zhe-Yi Hu; Jingtao Lu; Yuansheng Zhao
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.